Send to printer »

GEN News Highlights : Sep 17, 2007

bioMérieux to Design Companion Test for Ipsen Breast Cancer Compound

Assay will predict which patients are best suited to the therapeutic that targets the steroid sulfatase enzyme.

bioMérieux agreed to develop a companion test for Ipsen’s Phase I breast cancer drug candidate. The assay is intended for both the clinical development of the compound as well as a diagnostic test  potentially for future commercialization.

BN 83495 is designed to block the steroid sulfatase enzyme (STS), which is found in hormone-dependent breast cancer in postmenopausal women. bioMérieux will devise a tool to determine the patients best suited to benefit from this STS inhibitor.

The test will be developed on bioMérieux’ NucliSENS EasyQ® molecular diagnostics platform, using the NASBA® amplification technology. The company will will co-fund the project with Ipsen.